FDG PET in the management of patients with adrenal masses and Adrenocortical carcinoma

Hormones and Cancer

Volumn 2, Issue 6, 2011, Pages 354-362

  Deandreis, Désirée ^a   Leboulleux, Sophie ^a   Caramella, Caroline ^a   Schlumberger, Martin ^a   Baudin, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Adrenal; Adrenocortical carcinoma; Incidentaloma; PET

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENAL INCIDENTALOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL CARCINOMA; ANIMALS; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 83555177248     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0091-5     Document Type: Article

References (82)

1. Abgral R, Leboulleux S, Deandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E (2011) Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96(3): 665-671.
2. Ahmed M, Al-Sugair A, Alarifi A, Almahfouz A, Al-Sobhi S (2003) Whole-body positron emission tomographic scanning in patients with adrenal cortical carcinoma: comparison with conventional imaging procedures. Clin Nucl Med 28(6): 494-497.
3. Ansquer C, Scigliano S, Mirallié E, Taïeb D, Brunaud L, Sebag F, Leux C, Drui D, Dupas B, Renaudin K, Kraeber-Bodéré F (2010) 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation. Eur J Nucl Med Mol Imaging 37(9): 1669-1678.
4. Assie G, Antoni G, Tisiier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Scghlumberger M, Baudin E (2007) Prognostic parameters of metastastic adrenocortical carcinoma. J Clin Endo Metab 92: 148-154.
5. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M (2001) Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92(6): 1385-1392.
6. Bauditz J, Quinkler M, Wermke W (2009) Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer-a case report and review of the literature. Exp Clin Endocrinol Diabetes 117(7): 316-319.
7. Becherer A, Vierhapper H, Potzi C, Karanikas G, Kurtaran A, Schmaljohann J, Staudeherz A, Dudczak R, Kletter K (2001) FDG PET in adrenocortical carcinoma. Cancer Biother Radiopharm 4: 289-295.
8. Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Långström B (2000) PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 41(2): 275-282.
9. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12(3): 657-666.
10. Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF, Mueller PR, Hahn PF, Boland GW (2006) Distinguish benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 238: 578-585.
11. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fishmann AJ, Mueller PR, Boland GW (2006) Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology 238: 970-977.
12. Boland GW, Blake MA, Holalkere NS, Hahn PF (2009) PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol 192(4): 956-962.
13. Boland GW, Dwamena BA, Sangwaiya MJ, Goehler AG, Blake MA, Hahn PF, Scott JA, Kelra MK (2011) Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259: 117-126.
14. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR (1998) Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171(1): 201-204.
15. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, Angeli A, Terzolo M (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29: 298-302.
16. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11: 161-165.
17. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G (2001) GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92(5): 1144-1150.
18. Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL (2007) Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol 14: 468-475.
19. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, Raghupathi KI (2002) Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222(3): 629-633.
20. Caron P, Tabarin A (2010) 2010 Congress of the French Society of Endocrinology at Deauville. Ann Endocrinol 71(Suppl 1): S1-S2.
21. Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S, Baudin E (2010) Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol 21(10): 1527-1532.
22. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13): 1753-1759.
23. Cooper R, Sarioǧlu S, Sökmen S, Füzün M, Küpelioǧlu A, Valentine H, Görken IB, Airley R, West C (2003) Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89(5): 870-876.
24. de Baère T, Palussière J, Aupérin A, Hakime A, Abdel-Rehim M, Kind M, Dromain C, Ravaud A, Tebboune N, Boige V, Malka D, Lafont C, Ducreux M (2006) Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 240(2): 587-596.
25. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, Deschamps F, Rao P, Schlumberger M, de Baère T (2011) Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 258(1): 270-276.
26. Dromain C, Leboulleux S, AuperinA GD, Malka D, Lumbroso J, Schlumberger M, Sigal R, Elias D (2008) Staging of peritoneal carcinomatosis: enhanced CT vs PET/CT. Abdom Imag 33: 87-93.
27. Eckert AW, Lautner MH, Taubert H, Schubert J, Bilkenroth U (2008) Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep 20(6): 1381-1385.
28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247.
29. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115(2): 243-250.
30. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M (2009) Glucose transporter GLUT1 expression is a stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 16: 919-928.
31. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24): 3746-3752.
32. Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, Libé R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F (2009) 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 94(5): 1713-1722.
33. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69(5): 947-951.
34. Haider MA, Ghai S, Jhaveri K, Lockwood G (2004) Chemical shift MR imaging of hyperattenuating (> 10 HU) adrenal masses: does it still have a role? Radiology 231(3): 711-716.
35. Han SJ, Kim TS, Jeon SW, Jeong SJ, Yun M, Rhee Y, Kang ES, Cha BS, Lee EJ, Lee HC, Lim SK (2007) Analysis of adrenal masses by 18F-FDG positron emission tomography scanning. Int J Clin Pract 61(5): 802-809.
36. Harrison LE, Gaudin PB, Brenann MF (1999) Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134: 181-185.
37. Hennings J, Hellman P, Ahlström H, Sundin A (2009) Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 69: 314-323.
38. Hennings J, Lindhe O, Bergström M, Långström B, Sundin A, Hellman P (2006) [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91(4): 1410-1414.
39. Icard P, Goudet P, Chrapeney C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25: 891-897.
40. Israel GM, Korobnik M, Wang C, Hecht EN, Krinsky GA (2004) Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 183: 215-219.
41. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD (2006) FDG PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 33: 29-35.
42. Jr Y (2007) Clinical practice. The incidentally discovered adrenal mass. N Eng J Med 356: 601-610.
43. Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B (2003) 11C-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30(3): 403-410.
44. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F (1998) CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170: 747-752.
45. Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, Dunnick NR, Heiken JP, Wang HH (1996) Adrenal adenomas: relationship between histologic lipid and CT and MRI findings. Radiology 200: 743-747.
46. Kreissig R, Amthauer H, Krude H, Steinmueller P, Stroszczynski C, Hosten N, Grueters A, Felix R (2000) The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 30(5): 306.
47. Leboulleux S, Deandreis D, Escourrou C, Al Ghuzlan A, Bidault F, Aupérin A, Travagli JP, Lumbroso J, Schlumberger M, Baudin E (2011) Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol 164(1): 89-94.
48. Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91(3): 920-925.
49. Luton JP, Cerda S, Bilalud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A, Bricaire H (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1200.
50. Luton JP, Martinez M, Coste J, Bertherat J (2000) Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 143: 111-117.
51. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE (2006) Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 91(7): 2665-2671.
52. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17(3): 797-807.
53. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M (2001) The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 42(6): 884-892.
54. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E (2006) 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 47(1): 32-37.
55. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214.
56. Niekel MC, Bipat S, Stoker J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257(3): 674-684.
57. Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR (2000) Characterisation of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 217: 798-802.
58. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16(3): 907-918.
59. Sangwaiya MJ, Boland GW, Cronin CG, Blake MA, Halpern EF, Hahn PF (2010) Incidental adrenal lesions: accuracy of characterization with contract-enhanced washout multidetector CT-10 minute delayed imaging protocol revisited in a large patient cohort. Radiology 256: 504-510.
60. Schulick RD, Brennan MF (1999) Long term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6: 719-726.
61. Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H (2010) 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med 51(12): 1833-1840.
62. Song JH, Chuadhry FS, Mayo-Smith W (2008) The incidental indeterminate adrenal mass on CT: prevalence of adrenal disease in 1049 consecutive adrenal masses in patients with known malignancy. AJR Roentgenol 190: 1163-1168.
63. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP, Brennan MF (2002) Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 20(4): 941-950.
64. Suzuki A, Kawano T, Takahashi N, Lee J, Nakagami Y, Miyagi E, Hirahara F, Togo S, Shimada H, Inoue T (2004) Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imag 31: 1413-1420.
65. Tenenbaum F, Groussin L, Foehrenbach H, Tissier F, Gouya H, Bertherat J, Dousset B, Legmann P, Richard B, Bertagna X (2004) 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. Eur J Endocrinol 150(6): 789-792.
66. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, Borretta G, Papini E, Garofalo P, Allolio B, Dupas B, Mantero F, Tabarin A, Italian Association of Clinical Endocrinologists (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164(6): 851-857.
67. Tessonier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, Conte-Devolx B, Henry JF, Mundler O, Taieb D (2008) Does 18F-FDG PET add diagnostic accuracy in incidentally identified non-secreting adrenal tumors? Eur J Nucl Med Mol Imaging 35: 2018-2025.
68. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94(12): 4757-4767.
69. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J (1994) Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 35(12): 1965-1969.
70. Travaini LL, Trifirò G, Ravasi L, Monfardini L, Della Vigna P, Bonomo G, Chiappa A, Mallia A, Ferrari M, Orsi F, Paganelli G (2008) Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 35(7): 1316-1322.
71. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM (2003) Peritoneal carcinomatosis: role of 18F-FDG PET. J Nucl Med 44: 1407-1412.
72. Vikram R, Yeung HD, Macapinlac HA, Iyer RB (2008) Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. AJR Am J Roentgenol 191(5): 1545-1551.
73. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW (1996) Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 78(10): 2216-2222.
74. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1): 122S-150S.
75. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ (1999) [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84(7): 2291-2302.
76. Weiss LM (1984) Comparative histologic study of 43 metastasizing and non metastasizing adrenocortical tumors. Am J Surg Pathol 8: 163-169.
77. Weiss LM, Medeiros LJ, Vickery AL (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Path 13(3): 202-206.
78. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T (2003) Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 97(3): 554-560.
79. Young WF Jr (2000) Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29: 159-185.
80. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782.
81. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42: 1795-1799.
82. Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K (2004) Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and 11β-hydroxylase tracer 11C-metomidate. Eur J Nucl Med Mol Imag 31: 1224-1230.